
This version is available at https://strathprints.strath.ac.uk/28515/

Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.uk
We conclude that the THLE-CYP cell model enables in vitro investigation of both CYP independent and CYP mediated processes which may contribute to DILI, and also exploration of underlying mechanisms (e.g. bioactivation of clozapine by 2D6). If used in drug discovery, this approach has the potential to aid in rational design and selection of compounds with reduced DILI liability, and could enable early de-selection of drug candidates with significant potential to cause DILI in man.

References

doi:10.1016/j.tox.2010.08.105

P26
Evaluation of the relationship between inhibition of the bile salt export pump in vitro and risk of drug-induced liver injury in man
Sarah Dawson∗, Simone Stahl, Jane Barber, Claire Summers, Nikki Paul, J. Gerald Kenna.
Molecular Toxicology, Safety Assessment UK, AstraZeneca, Macclesfield, SK10 4TG, UK
E-mail address: Sarah.Dawson@astrazeneca.com (S. Dawson).

It has been proposed, that inhibition of hepatobiliary transporters may play an important role in the development of drug-induced liver injury (DILI) (Wagner, 2009; Stieger, 2007). To provide further understanding of the relationship between inhibition of the canicular transporter bile salt efflux pump (Bsep; Abcb11) and DILI in man, we have assessed inhibition of Bsep activity in vitro by hepatotoxic and non-hepatotoxic marketed drugs.

Inhibition of rat Bsep was analysed in inverted plasma membrane vesicles prepared from transfected Sf21 insect cells. We quantified the adenosine triphosphate (ATP)-dependent uptake of the probe substrate [3H]-taurocholate by a rapid filtration technique (Stieger et al., 2000). In addition, inhibition of Bsep function in sandwich-cultured primary rat hepatocytes was assessed using an in vitro model of chronic low level toxic insult (Stieger et al., 2000). In addition, inhibition of Bsep function in sandwich-cultured primary rat hepatocytes was assessed using an in vitro model of chronic low level toxic insult (Stieger et al., 2000). In addition, inhibition of Bsep function in sandwich-cultured primary rat hepatocytes was assessed using an in vitro model of chronic low level toxic insult (Stieger et al., 2000).

Potent inhibition of rat Bsep activity in vesicles (IC50 < 300 μM) was observed with 22/42 drugs (52%) associated with cholestatic or mixed liver injury in man, 6/25 drugs (32%) associated with hepatocellular liver injury and 5/23 non-hepatotoxic drugs (17%) (Fig. 1A).

A high correlation between potency of rat Bsep inhibition in vesicles and hepatocytes was observed (r2 = 0.79). However, the apparent potency of inhibition was greater in hepatocytes than in vesicles for many of the tested drugs (Fig. 1B). The compounds that exhibited potent inhibition of Bsep in both experimental systems included the withdrawn drugs troglitazone and nefazodone, and bosentan and ketoconazole, both of which have a DILI black box warning.

We conclude that potent Bsep inhibition by drugs correlates with increased risk of cholestatic drug hepatotoxicity in man, and that in vitro evaluation of this liability is useful for DILI hazard identification.

doi:10.1016/j.tox.2010.08.106

P27
Oxidative stress via hydrogen peroxide and Menadione does not induce the secretion of IGFBP-5 in primary rat hepatocytes
Emma M. Large1∗, Catherine J. Henderson1, David J. Flint2, M. Helen Grant1
1 Bioengineering Unit, University of Strathclyde, Glasgow, G4 0NW, United Kingdom
2 SIPBS, University of Strathclyde, Glasgow, G4 0NW, United Kingdom
E-mail address: m.h.grant@strath.ac.uk (E.M. Large).

Mortality rates are on the increase from liver disease in the developed world, particularly in Scotland. The liver has an enormous capacity for wound repair and regeneration after injury, but early diagnosis is essential. Despite the high number of deaths each year from liver disease, hepatologists still lack relevant diagnostic biomarkers to detect early liver disease.

The aim of this project is to identify a suitable biomarker to detect early liver disease. Insulin-like growth factor binding protein-5 (IGFBP-5) is one such potential biomarker. IGFBP-5 has already been shown to be upregulated in skin fibrosis (Yasuoka et al., 2006a), fibrosis of the lung (Yasuoka et al., 2006b) and has been identified as a genetic marker for intrahepatic cholangiocarcinoma (Blechacz and Gores, 2008). Its role in liver damage is being investigated using an in vitro model of chronic low level toxic insult in primary cultures of rat hepatocytes (male Sprague–Dawley rats, 180–220 g).

The effects of low concentrations of two oxidative toxins (Menadione (0.1, 1, 5 and 10 μM) and hydrogen peroxide (0.01, 0.05,

Fig. 1. Inhibition of rat Bsep activity by DILI compounds in vesicles (A) and correlation of IC50 values between vesicles and hepatocytes (B).
...0.1 and 0.5 mM)) were assessed over a period of 9 days in culture. Fresh toxin was added daily and the Williams’ E medium changed every three days. Toxicity via oxidative stress was assessed by measuring reduced glutathione (GSH) content and WST-1 assay (Roche Applied Science, cat. no. 11 644 807 001). The cell number was assessed using crystal violet (CV) staining and IGFBP-5 secretion into the medium was measured using a sandwich ELISA assay.

Oxidative stress was observed and both toxins caused a significant decrease in GSH content. After 4 days exposure to 5 μM Menadione, GSH content had declined to 2.97 ± 0.21 nmol/well compared with controls (3.73 ± 0.03 nmol/well). The corresponding value after 0.01 mM H2O2 exposure was 3.40 ± 0.20 nmol/well in comparison with controls (4.22 ± 0.18 nmol/well) (P < 0.05). Cell death was not observed until 9 days exposure to the toxins when CV staining was significantly decreased (P < 0.05). IGFBP-5 secretion into the medium was lower in samples from cells following exposure to toxins than in the control samples taken at the same time points (Fig. 1). It should be noted that IGFBP-5 secretion increased in the control samples between 3 and 9 days in culture (P < 0.05). These results suggest that IGFBP-5 secretion may be associated with de-differentiation, and have a role in the decline of cellular function in hepatocytes during culture, but does not appear to be involved in toxicity by oxidative stress as induced by Menadione and hydrogen peroxide.

Acknowledgement: EML is an EPSRC funded student.

References


doi:10.1016/j.tox.2010.08.107

Fig. 1. IGFBP-5 release from primary rat hepatocytes exposed to Menadione and hydrogen peroxide was measured using media samples collected over 0–3 days, 3–6 days and 6–9 days (results are mean ± SEM, n = 3, *P < 0.05, by one-way ANOVA followed by Dunnett’s multiple comparison test).

P28

Protein binding and pharmacokinetics of reactive acyl glucuronide drug metabolites

Thomas G. Hammond 1,∗, Sophie L. Regan 1,∗, Xiaoli Meng 1, James L. Maggs 1, Rosalind E. Jenkins 1, Gerry L. Kenny 2, Jean G. Sathish 1, Dominic P. Williams 1, B. Kevin Park 1

1 MRC Centre for Drug Safety Science, Department Pharmacology and Therapeutics, Sherrington Building, Ashton Street, The University of Liverpool, Liverpool, L693CE, UK
2 Molecular Toxicology, Safety Assessment UK, 23569 Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK

E-mail address: Thomas.hammond@liverpool.ac.uk (T.G. Hammond).

Tolmetin and diclofenac are members of the non-steroidal anti-inflammatory class of drugs (NSAIDs). Many NSAIDs have been associated with idiosyncratic toxicity, manifesting in hepatotoxicity or hypersensitivity reactions. These adverse reactions have been suggested to be a result of bioactivation to protein reactive metabolites. It is hypothesised that acyl glucuronide (AG) metabolites are sufficiently protein reactive to elicit an idiosyncratic reaction through the initiation of an immune response (Bailey and Dickenson, 2003). We have investigated this possibility through the incubation of the synthetic AG metabolites of diclofenac and tolmetin with human, rat and mouse serum albumin. We have investigated the metabolism of two NSAIDs into their AG metabolites, their AG-mediated protein binding, and are currently investigating rates of AG clearance in the rat.

Tolmetin acyl glucuronide (T-AG) and diclofenac acyl glucuronide (D-AG) were incubated with human serum albumin (HSA) at increasing concentrations for 16 h at 37 °C, with AG covalent adduct formation assessed using LC–MS/MS technology (AB Sciex QTRAP 5500.)

Male Wistar rats were anaesthetized using 14% urethane, with the bile duct and carotid artery cannulated. Tolmetin was then administered orally at a dose of 10 mg/kg, with bile and blood samples collected over 4h for pharmacokinetic analysis (n = 3). Following anesthesia, the femoral vein of male Wistar rats were cannulated with D-AG administered through this route at a dose of 60 mg/kg. Blood samples were collected, and albumin was isolated using preparative HPLC. Adducts were searched for using an AB Sciex QTRAP 5500 LC–MS/MS technology (Table 1).

Following in vitro incubation of T-AG with rat (RSA) and mouse (MSA) serum albumin, following the same procedure as for HSA, fewer amino acids were found to be modified at higher concentrations and adducts were not found at lower concentrations of 1:1 molar ratios, unlike following incubation with HSA. No albumin adducts were detected following i.v. administration of D-AG at

E-mail address: Thomas.hammond@liverpool.ac.uk (T.G. Hammond).